Sugi Predict

Sugi Predict / Compounds / SCHEMBL2901146

SCHEMBL2901146

SCHEMBL2901146

Cc1nccnc1-c1ccc(CC(=O)N[C@H](C)c2ccc(OCC(F)(F)F)cn2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CACNA1I Q9P0X4 4/20 1.00
▸ CACNA1G O43497 2/20 0.71
▸ CACNA1H O95180 2/20 0.71
▸ CNR2 P34972 1/20 0.71
▸ KCNH2 Q12809 1/20 0.71
▸ KMT2A Q03164 1/20 0.42
▸ HDAC4 P56524 1/20 0.38
▸ HDAC6 Q9UBN7 1/20 0.38
▸ SLC22A12 Q96S37 1/20 0.38
▸ ALDH1A1 P00352 2/20 0.37
▸ MAPT P10636 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ WNT3A P56704 3/20 0.37
▸ IDH1 O75874 2/20 0.36
▸ PTGDR2 Q9Y5Y4 1/20 0.36
▸ HTT P42858 2/20 0.36
▸ SUCNR1 Q9BXA5 1/20 0.36
▸ RORC P51449 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20328496 0.93 CACNA1I (0.86) CACNA1ICACNA1GCACNA1HCNR2KCNH2
SCHEMBL22025711 0.90 CACNA1I (0.81) CACNA1ICACNA1GCACNA1HCNR2KCNH2
SCHEMBL2908523 0.87 CACNA1I (0.76) CACNA1ICACNA1GCACNA1HCNR2KCNH2
SCHEMBL1063200 0.85 CACNA1I (0.75) CACNA1ICACNA1GCACNA1HCNR2KCNH2
SCHEMBL3053738 0.85 CACNA1I (0.74) CACNA1ICACNA1GCACNA1HCNR2KCNH2
SCHEMBL1060457 0.84 CACNA1I (0.82) CACNA1ICACNA1GCACNA1HCNR2KCNH2
SCHEMBL1063551 0.83 CACNA1I (0.71) CACNA1ICACNA1GCACNA1HCNR2KCNH2
SCHEMBL1059302 0.83 CACNA1I (0.71) CACNA1ICACNA1GCACNA1HCNR2KCNH2
SCHEMBL1062007 0.83 CACNA1I (0.71) CACNA1ICACNA1GCACNA1HCNR2KCNH2
Suvecaltamide SCHEMBL21828396 0.83 CACNA1I (1.00) CACNA1ICACNA1GCACNA1HCNR2KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119264193-A Strong coordination PNN tridentate chiral ligand based on inversion effect and application thereof in free radical asymmetric functionalization and related reaction 武汉大学 2025-01-07 — — CN claimed
EP-2212291-B1 HETEROCYCLE PHENYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS MERCK SHARP & DOHME (US) 2014-06-04 — — EP claimed
US-8637513-B2 Heterocycle phenyl amide T-type calcium channel antagonists MERCK SHARP & DOHME CORP. (US) 2014-01-28 — — US claimed
US-20100261724-A1 HETEROCYCLE PHENYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS MERCK SHARP & DOHME LLC 2010-10-14 — — US claimed
EP-2212291-A1 HETEROCYCLE PHENYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS Merck Sharp & Dohme Corp. (US) 2010-08-04 — — EP claimed
WO-2009054984-A1 HETEROCYCLE PHENYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS MERCK & CO., INC. (US) 2009-04-30 — — WO claimed
CN-119264193-A Strong coordination PNN tridentate chiral ligand based on inversion effect and application thereof in free radical asymmetric functionalization and related reaction 武汉大学 2025-01-07 — — CN disclosed
CN-119264193-A Strong coordination PNN tridentate chiral ligand based on inversion effect and application thereof in free radical asymmetric functionalization and related reaction 武汉大学 2025-01-07 — — CN disclosed
EP-3615010-B1 METHODS FOR TREATING DRAVET SYNDROME CAVION INC (US) 2024-08-21 — — EP disclosed
CN-110770221-B Methods for improving memory and cognition and for treating memory and cognition disorders 卡维昂公司 2023-09-08 — — CN disclosed
CN-115073383-B Synthesis method of aryl acetic acid compound 四川大学 2023-07-18 — — CN disclosed
CN-114539137-B Chiral alpha-heteroaryl amine and preparation method thereof 河北工业大学 2023-06-23 — — CN disclosed
EP-3364993-B1 METHODS FOR TREATING ANGELMAN SYNDROME CAVION INC (US) 2022-11-09 — — EP disclosed
US-8637513-B2 Heterocycle phenyl amide T-type calcium channel antagonists MERCK SHARP & DOHME CORP. (US) 2014-01-28 — — US disclosed
US-8637513-B2 Heterocycle phenyl amide T-type calcium channel antagonists MERCK SHARP & DOHME CORP. (US) 2014-01-28 — — US disclosed
US-8637513-B2 Heterocycle phenyl amide T-type calcium channel antagonists MERCK SHARP & DOHME CORP. (US) 2014-01-28 — — US disclosed
US-20100261724-A1 HETEROCYCLE PHENYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS MERCK SHARP & DOHME LLC 2010-10-14 — — US disclosed
US-20100261724-A1 HETEROCYCLE PHENYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS MERCK SHARP & DOHME LLC 2010-10-14 — — US disclosed
US-20100261724-A1 HETEROCYCLE PHENYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS MERCK SHARP & DOHME LLC 2010-10-14 — — US disclosed
WO-2009054984-A1 HETEROCYCLE PHENYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS MERCK & CO., INC. (US) 2009-04-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261724-A1 HETEROCYCLE PHENYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS CACNA1G, CACNA1H, CACNA1I CACNA1I 3/4885CACNA1G 1/4885CACNA1H 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.